A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.

Moulder, Stacy; Gladish, Gregory; Ensor, Joe; Gonzalez-Angulo, Ana Maria; Cristofanilli, Massimo; Murray, James L; Booser, Daniel; Giordano, Sharon H; Brewster, Abeena; Moore, Julia; Rivera, Edgardo; Hortobagyi, Gabriel N; Tran, Hai T

Moulder, Stacy; Gladish, Gregory; Ensor, Joe; Gonzalez-Angulo, Ana Maria; Cristofanilli, Massimo; Murray, James L; Booser, Daniel; Giordano, Sharon H; Brewster, Abeena; Moore, Julia; Rivera, Edgardo; Hortobagyi, Gabriel N; Tran, Hai T.

Affiliation

Moulder S; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. smoulder@mdanderson.org

Cancer ; 118(9): 2378-84, 2012 May 01.

Article in En | MEDLINE | ID: mdl-22006179

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Sirolimus/analogs & derivatives; Taxoids/administration & dosage; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics; Docetaxel; Drug Administration Schedule; Early Termination of Clinical Trials; Everolimus; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia/chemically induced; Sirolimus/administration & dosage; Sirolimus/pharmacokinetics; Taxoids/pharmacokinetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Sirolimus / Taxoids Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Cancer Year: 2012 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google